ArticlePloS one2026
Computational and immunoinformatics approaches for designing phytocompound-based drugs and a multi-epitope vaccine targeting FemA, a cell wall protein of Staphylococcus aureus.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus, a bacterial pathogen, is increasingly linked to severe healthcare-associated diseases, from mild skin infections to toxic shock syndrome. Due to limitations in conventional methods, we use computational techniques to screen potential phytocompounds for new drug development and to construct a multiepitope vaccine. Aminoacyltransferase FemA, essential for peptidoglycan formation, was chosen as the target protein for drug and vaccine development. Meanwhile, 1100 phytocompounds were retrieved from 54 plants using the NPASS database and analyzed for drug-likeness and ADMET properties. Paulownin was selected for its higher binding affinity (-7.78 Kcal/mol) than the control drug, Doxycycline (-7.5 Kcal/mol) in molecular docking. It also showed lower RMSD, RMSF, and stronger hydrogen bonding (1.11/0.8 Å, 1.594/1.613 Å, and 3/2, respectively) in molecular dynamics simulations. It demonstrated potential higher affinity, scoring -39.74 ± 6.05 Kcal/mol, outperforming Doxycycline's -28.15 ± 5.90 Kcal/mol in MM-GBSA. For the vaccine, 12 selected epitopes were compiled utilizing GPGPG, two KK peptides, and AAY linkers. The N-flanking immunogenicity of the vaccine was enhanced by adding a lipoprotein adjuvant, LprG. The vaccine alone and the vaccine with the receptor molecule TLR2 showed RMSF (4.247 Å/2.42 Å), RMSD (12.9 Å/7.52 Å), SASA (228.48 nm²/220.29 nm²), Rg (33.76 Å/28.48 Å), and hydrogen bonds (171/165), indicating the vaccine's predicted immune response patterns. These findings computationally prioritize Paulownin and the multi-epitope construct as candidates for further experimental evaluation. As the study is entirely in silico, experimental validation is required to confirm biological activity and immunogenicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.